Gao et al. [43] proved that treating prostate cancer with ipilimumab can lead to a compensatory up-regulation of VISTA, indicating that VISTA may be related to the development of resistance to immune checkpoint blocking therapy. The gene discussed is VSIR; the disease is Familial prostate cancer.